IL-6在肺动脉高压中的研究进展
Advances of Interleukin-6 in Pulmonary Hypertension
陈婷婷 1杨进 2芦殿香2
作者信息
- 1. 青海大学医学院,西宁 810001
- 2. 成都大学附属医院,成都 610086
- 折叠
摘要
白细胞介素-6(interleukin-6,IL-6)是一种多效性细胞因子,在炎症反应中起重要作用.越来越多的证据表明,IL-6在肺动脉高压的发生发展中也起到了十分重要的作用,肺动脉高压患者和动物模型的循环中IL-6水平明显升高,小鼠体内过表达IL-6可以诱导重度肺动脉高压,针对IL-6的治疗可以改善肺动脉高压.本文主要从分子水平对IL-6在肺动脉高压中的作用及其机制的研究进展进行综述,并对目前以IL-6为靶点治疗肺动脉高压的候选方案进行介绍,以期为肺动脉高压的临床药物研究开发提供参考.
Abstract
Interleukin-6(IL-6)is a pleiotropic cytokine,which plays an important role in the inflammatory response.There is increasing evidence that IL-6 also plays a very important role in the development of pulmonary hypertension,as evidenced by the fact that circulating levels of IL-6 are significantly elevated in pulmonary hypertension patients and animal models,that overexpression of IL-6 in mice can induce severe pulmonary hypertension,and that treatment targeting IL-6 can improve pulmonary hypertension.This paper reviews the research progress on the role of IL-6 in pulmonary hypertension and its mechanism at the molecular level,and introduce the current candidate regimens targeting IL-6 for the treatment of pulmonary hypertension,in order to provide a reference for clinical drug research and development for pulmonary hypertension.
关键词
白细胞介素-6/肺动脉高压/肺动脉平滑肌细胞/肺血管重塑/作用机制Key words
interleukin-6/pulmonary hypertension/pulmonary arterial smooth muscle cell/pulmonary vascular remodeling/effect and mechanism引用本文复制引用
基金项目
青海省科技厅自然科学基金项目(2024-ZJ-945)
国家自然科学基金项目(82374148)
国家自然科学基金项目(82060786)
国家重点研发计划(2022YFB2303201)
青海大学青年科研基金项目(2023-QYY-5)
出版年
2024
NETL
NSTL
万方数据